Patents by Inventor Giovanna Pitarresi
Giovanna Pitarresi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11633356Abstract: Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.Type: GrantFiled: August 3, 2020Date of Patent: April 25, 2023Assignee: DISTRETTO TECNOLOGICO SICILIA MICRO E NANO SISTEMI S.C.A.R.L.Inventors: Anna Rita Blanco, Maria Luisa Bondi', Gennara Cavallaro, Grazia Maria Letizia Consoli, Emanuela Fabiola Craparo, Gaetano Giammona, Mariano Licciardi, Giovanna Pitarresi, Guiseppe Granata, Patrizia Saladino, Clara La Marca, Irene Ceidda, Salvatore Papasergi, Patrizia Guarneri, Salvatore Cuzzocrea, Emanuela Esposito, Santa Viola
-
Patent number: 11285136Abstract: Described herein are loaded nanoparticles of Sorafenib (Sorafenib PBB) or Sorafenib derivatives (Sorafenib PBB derivatives), wherein the nanoparticles are polymeric PBB nanoparticles, (PHEA-BIB-pButMA, ?,?-poly(N-2-hydroxyethyl)-co-{N-2-ethylene-[2-(poly(butylmethacrylate)-isobutyrate]}-D, L-aspartamide, as well as a method for obtaining them. Also described herein are a controlled release formulation of Sorafenib or Sorafenib, derivatives that include Sorafenib PBB or Sorafenib PBB derivatives, and to the use of the formulation in the treatment of tumor diseases of the kidney, liver, thyroid, colon, breast, pancreas, lungs and/or recurrent glioblastoma.Type: GrantFiled: February 8, 2018Date of Patent: March 29, 2022Assignee: DISTRETTO TECNOLOGICO SICILIA MICRO E NANO SISTEMI S.C.A.R.L.Inventors: Giovanna Pitarresi, Melchiorre Cervello, Antonina Azzolina, Roberto Puleio, Guido Ruggero Loria, Stefano Puleo, Gaetano Giammona
-
Patent number: 11266659Abstract: Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.Type: GrantFiled: October 9, 2015Date of Patent: March 8, 2022Assignee: DISTRETTO TECNOLOGICO SICILIA MICRO E NANO SISTEMI S.C.A.R.L.Inventors: Anna Rita Blanco, Maria Luisa Bondi', Gennara Cavallaro, Grazia Maria Letizia Consoli, Emanuela Fabiola Craparo, Gaetano Giammona, Mariano Licciardi, Giovanna Pitarresi, Giuseppe Granata, Patrizia Saladino, Clara La Marco, Irene Ceidda, Salvatore Papasergi, Patrizia Guarneri, Salvatore Cuzzocrea, Emanuela Esposito, Santa Viola
-
Patent number: 11253526Abstract: Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.Type: GrantFiled: August 3, 2020Date of Patent: February 22, 2022Assignee: DISTRETTO TECNOLOGICO SICILIA MICRO E NANO SISTEMI S.C.A.R.L.Inventors: Anna Rita Blanco, Maria Luisa Bondi′, Gennara Cavallaro, Grazia Maria Letizia Consoli, Emanuela Fabiola Craparo, Gaetano Giammona, Mariano Licciardi, Giovanna Pitarresi, Guiseppe Granata, Patrizia Saladino, Clara La Marca, Irene Deidda, Salvatore Papasergi, Patrizia Guarneri, Salvatore Cuzzocrea, Emanuela Esposito, Santa Viola
-
Publication number: 20220031614Abstract: Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.Type: ApplicationFiled: August 3, 2020Publication date: February 3, 2022Inventors: Anna Rita BLANCO, Maria Luisa BONDI', Gennara CAVALLARO, Grazia Maria Letizia CONSOLI, Emanuela Fabiola CRAPARO, Gaetano GIAMMONA, Mariano LICCIARDI, Giovanna PITARRESI, Guiseppe GRANATA, Patrizia SALADINO, Clara LA MARCA, Irene CEIDDA, Salvatore PAPASERGI, Patrizia GUARNERI, Salvatore CUZZOCREA, Emanuela ESPOSITO, Santa VIOLA
-
Publication number: 20210046083Abstract: Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.Type: ApplicationFiled: August 3, 2020Publication date: February 18, 2021Inventors: Anna Rita BLANCO, Maria Luisa BONDI', Gennara CAVALLARO, Grazia Maria Letizia CONSOLI, Emanuela Fabiola CRAPARO, Gaetano GIAMMONA, Mariano LICCIARDI, Giovanna PITARRESI, Guiseppe GRANATA, Patrizia SALADINO, Clara LA MARCA, Irene CEIDDA, Salvatore PAPASERGI, Patrizia GUARNERI, Salvatore CUZZOCREA, Emanuela ESPOSITO, Santa VIOLA
-
Patent number: 10709787Abstract: The present invention relates to a composition comprising hydrogels from functionalized hyaluronic acid derivatives, said hydrogels loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP) intended for the oral treatment of celiac disease. Specifically, this invention concerns a one-pot methodology useful to prepare methacrylic derivatives of hyaluronic acid, through the formation of a specific active group on hydroxyl groups of hyaluronic acid, the subsequent substitution of the inserted active group with ethylenediamine and finally, the reaction with methacrylic anhydride. The obtained methacrylic hyaluronic acid derivatives are used to prepare hydrogels through irradiation and loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP). The ability of prepared hydrogels to allow the enzyme release, as active form in simulated gastrointestinal fluids is proved.Type: GrantFiled: May 6, 2015Date of Patent: July 14, 2020Assignee: NEMYSIS LIMITEDInventors: Giovanna Pitarresi, Fabio Salvatore Palumbo, Gaetano Giammona
-
Publication number: 20200000783Abstract: Described herein are loaded nanoparticles of Sorafenib (Sorafenib PBB) or Sorafenib derivatives (Sorafenib PBB derivatives), wherein the nanoparticles are polymeric PBB nanoparticles, (PHEA-BIB-pButMA, ?,?-poly(N-2-hydroxyethyl)-co-{N-2-ethylene-[2-(poly(butylmethacrylate)-isobutyrate]}-D, L-aspartamide, as well as a method for obtaining them. Also described herein are a controlled release formulation of Sorafenib or Sorafenib, derivatives that include Sorafenib PBB or Sorafenib PBB derivatives, and to the use of the formulation in the treatment of tumor diseases of the kidney, liver, thyroid, colon, breast, pancreas, lungs and/or recurrent glioblastoma.Type: ApplicationFiled: February 8, 2018Publication date: January 2, 2020Inventors: Giovanna Pitarresi, Melchiorre Cervello, Antonina Azzolina, Roberto Puleio, Guido Ruggero Loria, Stefano Puleo, Gaetano Giammona
-
Publication number: 20170049896Abstract: The present invention relates to a composition comprising hydrogels from functionalized hyaluronic acid derivatives, said hydrogels loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP) intended for the oral treatment of celiac disease. Specifically, this invention concerns a one-pot methodology useful to prepare methacrylic derivatives of hyaluronic acid, through the formation of a specific active group on hydroxyl groups of hyaluronic acid, the subsequent substitution of the inserted active group with ethylenediamine and finally, the reaction with methacrylic anhydride. The obtained methacrylic hyaluronic acid derivatives are used to prepare hydrogels through irradiation and loaded with exogenous enzymes selected in the group consisting of prolyl endopeptidase (PEP) and endoprotease (EP). The ability of prepared hydrogels to allow the enzyme release, as active form in simulated gastrointestinal fluids is proved.Type: ApplicationFiled: May 6, 2015Publication date: February 23, 2017Inventors: Giovanna Pitarresi, Fabio Salvatore Palumbo, Gaetano Giammona
-
Patent number: 9410000Abstract: In this invention a two steps procedure is described useful to insert functional groups to the hyaluronic acid (HA), through the formation, in organic solvent, of a particular active group on hydroxyl groups of HA and subsequent substitution, on the inserted active group, with a pendant portion containing at least in its terminal portion a nucleophilic functional group, NH2—R. The group inserted by nucleophilic substitution can contain in another its terminal portion a further nucleophilic functional group, in a way to be easily exploitable to further chemical functionalizations, such as an example to obtain the methacrylation of HA functional groups, to obtain photocrosslinkable derivatives. Both direct derivatives of the proposed process and those obtained by the further functionalization can be employed to produce hydrogels.Type: GrantFiled: November 13, 2014Date of Patent: August 9, 2016Assignee: UNIVERSITA' DEGLI STUDI DI PALERMOInventors: Gaetano Giammona, Fabio Palumbo, Giovanna Pitarresi
-
Patent number: 9283283Abstract: The present invention relates to hydrogels based on hyaluronic acid based derivatives, that are more resistant than hyaluronic acid alone towards chemical and enzymatic degradation and are endowed with a mix of chemical and mechanical properties such that they are of optimal use in several surgeries, for instance for injection in bone fractures or cavities and for the production of coatings of prostheses in orthopedic surgery, as fillers in cosmetic and maxillo-facial surgery, as anti-adhesion barrier in the prevention of postoperative adhesions in abdominal and abdominal/pelvic surgery, and in general surgery. These hydrogels can be loaded with several different kinds of compounds having pharmacological and biological activity, that are then released from the hydrogel in the site of intervention.Type: GrantFiled: July 29, 2011Date of Patent: March 15, 2016Assignees: MERO S.R.L., NOVAGENIT S.R.L.Inventors: Gaetano Giammona, Giovanna Pitarresi, Fabio Palumbo, Carlo Luca Romano′, Enzo Meani, Edgardo Cremascoli
-
Publication number: 20150183891Abstract: In this invention a two steps procedure is described useful to insert functional groups to the hyaluronic acid (HA), through the formation, in organic solvent, of a particular active group on hydroxyl groups of HA and subsequent substitution, on the inserted active group, with a pendant portion containing at least in its terminal portion a nucleophilic functional group, NH2—R. The group inserted by nucleophilic substitution can contain in another its terminal portion a further nucleophilic functional group, in a way to be easily exploitable to further chemical functionalizations, such as an example to obtain the methacrylation of HA functional groups, to obtain photocrosslinkable derivatives. Both direct derivatives of the proposed process and those obtained by the further functionalization can be employed to produce hydrogels.Type: ApplicationFiled: November 13, 2014Publication date: July 2, 2015Applicant: UNIVERSITA' DEGLI STUDI DI PALERMOInventors: Gaetano GIAMMONA, Fabio PALUMBO, Giovanna PITARRESI
-
Patent number: 8858999Abstract: In this invention a two steps procedure is described useful to insert functional groups to the hyaluronic acid (HA), through the formation, in organic solvent, of a particular active group on hydroxyl groups of HA and subsequent substitution, on the inserted active group, with a pendant portion containing at least in its terminal portion a nucleophilic functional group, NH2—R. The group inserted by nucleophilic substitution can contain in another its terminal portion a further nucleophilic functional group, in a way to be easily exploitable to further chemical functionalizations, such as an example to obtain the methacrylation of HA functional groups, to obtain photocrosslinkable derivatives. Both direct derivatives of the proposed process and those obtained by the further functionalization can be employed to produce hydrogels.Type: GrantFiled: January 30, 2009Date of Patent: October 14, 2014Assignee: Universita' Degli Studi di PalermoInventors: Gaetano Giammona, Fabio Palumbo, Giovanna Pitarresi
-
Patent number: 8529935Abstract: The present invention relates to hydrogels endowed with antibacterial properties, to be used for injection in damaged bones or in the production of antibacterial coatings of prostheses for implant in the human or animal body, obtained by loading with antibacterial agents hydrogels formed by derivatives of hyaluronic acid; the invention also relates to a kit of parts for producing the antibacterial hydrogels.Type: GrantFiled: January 29, 2010Date of Patent: September 10, 2013Assignees: Mero S.R.L., Novagenit S.R.L.Inventors: Gaetano Giammona, Giovanna Pitarresi, Fabio Palumbo, Carlo Luca Romano, Enzo Meani, Edgardo Cremascoli
-
Publication number: 20130129800Abstract: The present invention relates to hydrogels based on hyaluronic acid based derivatives, that are more resistant than hyaluronic acid alone towards chemical and enzymatic degradation and are endowed with a mix of chemical and mechanical properties such that they are of optimal use in several surgeries, for instance for injection in bone fractures or cavities and for the production of coatings of prostheses in orthopedic surgery, as fillers in cosmetic and maxillo-facial surgery, as anti-adhesion barrier in the prevention of postoperative adhesions in abdominal and abdominal/pelvic surgery, and in general surgery. These hydrogels can be loaded with several different kinds of compounds having pharmacological and biological activity, that are then released from the hydrogel in the site of intervention.Type: ApplicationFiled: July 29, 2011Publication date: May 23, 2013Applicants: MERO S.R.L., NOVAGENIT S.R.LInventors: Gaetano Giammona, Giovanna Pitarresi, Fabio Palumbo, Carlo Luca Romano', Enzo Meani, Edgardo Cremascoli
-
Publication number: 20110280921Abstract: The present invention relates to hydrogels endowed with antibacterial properties, to be used for injection in damaged bones or in the production of antibacterial coatings of prostheses for implant in the human or animal body, obtained by loading with antibacterial agents hydrogels formed by derivatives of hyaluronic acid; the invention also relates to a kit of parts for producing the antibacterial hydrogels.Type: ApplicationFiled: January 29, 2010Publication date: November 17, 2011Applicants: NOVAGENIT S.R.L., MERO S.R.LInventors: Gaetano Giammona, Giovanna Pitarresi, Fabio Palumbo, Carlo Luca Romano, Enzo Meani, Edgardo Cremascoli
-
Publication number: 20110236486Abstract: A system and method are provided for controlling an internal combustion engine driving a generator/welder or a stand-alone generator. Controlling the engine may include altering the engine speed based upon a detected demand on the generator and/or operating parameters of a welder. For example, the engine speed may be increased based on a detected draw on the generator and/or the operating parameters of the welder. In addition, the engine speed may be automatically decreased to a non-standard idle speed or the engine may be automatically turned off if no demand is detected for a period of time. Additionally, the engine speed may be increased if only frequency-insensitive demands are detected on the generator. Combinations of these and further methods may be executed. Various devices are provided for implementing the above methods.Type: ApplicationFiled: November 30, 2009Publication date: September 29, 2011Inventors: Gaetano Giammona, Fabio Palumbo, Giovanna Pitarresi
-
Publication number: 20080292664Abstract: Compositions and products based on the chemical crosslinking of hyaluronic acid with a polyfunctional polymer having a protein-like structure, bearing hydrazido pendent groups along the polymeric chain. The polymer is preferably, alpha-beta-polyaspartylhydrazide, a biocompatible macromolecule. The materials obtained after crosslinking, specifically hydrogels, undergo a reduced chemical and enzymatic degradation, unlike the starting hyaluronic acid, and they can be used to prepare systems for applications in the biomedical and pharmaceutical field.Type: ApplicationFiled: June 23, 2005Publication date: November 27, 2008Inventors: Gaetano Giammona, Giovanna Pitarresi, Fabio Salvatore Palumbo